Skip to content
CompletedPhase 1

Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans

NCT04032301 · University of Minnesota

Closed to entry
Status
Not accepting participants
Phase 1
Phase
67
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

Co-occurring post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) is the most common response to trauma; it is associated with poor clinical outcomes and substantial human disability. Veterans with both PTSD and MDD (PTSD+MDD) have been shown to be at much greater suicidal risk than individuals with only one of these disorders. Ketamine given as repeated infusions has been shown to be effective in rapidly reducing PTSD and MDD symptoms in treatment resistant PTSD+MDD individuals. However, knowledge about the mechanisms underlying comorbid PTSD and MDD remain limited. The purpose of this study is to use repeated ketamine infusions as a probe to validate a model of PTSD+MDD that focuses on neuroanatomy and executive functioning.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Montgomery-Asberg Depression Rating Scale (MADRS)

    Measured over At baseline, 60 minutes pre-infusion, 24 hours post-infusion, and after infusion series up to 2 months.

  • PTSD Symptom Scale-Interview for DSM-5 (PSS-I-5)

    Measured over At baseline, 60 minutes pre-infusion, 24 hours post-infusion, and after infusion series up to 2 months.

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 75 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria: For the PTSD+MDD group, inclusion criteria are: 1. Female/Male veterans 2. 18 to 75 years old 3. Meets DSM-5 criteria for MDD, single or recurrent, moderate-severe without psychotic features 4. Meets DSM-5 criteria for chronic PTSD or subthreshold PTSD \[meets criterion A (traumatic event), criterion B (intrusion symptoms), and 2 of the following 3 criteria: C (avoidance symptoms), D (negative alterations in cognitions and mood), or E (marked alterations in arousal and reactivity)\] 5. If applicable, 6 weeks of stable antidepressants/augmenting agents 6. Sixth grade reading level 7. Ability to provide consent For the Healthy Controls group, inclusion criteria are: 1. Female/Male veterans 2. 18 to 75 years old 3. Does not meet DSM-5 criteria for MDD, single or recurrent, moderate-severe without psychotic features 4. Does not meet DSM-5 criteria for chronic PTSD or subthreshold PTSD 5. Not on medications for managing a psychiatric indication 6. Sixth grade reading level 7. Ability to provide consent For the Depression-only group, inclusion criteria are: 1. Female/Male veterans 2. 18 to 75 years old 3. Experienced a traumatic event that meets DSM-5 criterion A for a diagnosis of PTSD but does not meet sufficient criteria (B-E) necessary for a diagnosis of PTSD or subthreshold PTSD 4. Meets criteria for MDD, single or recurrent, moderate-severe 5. If applicable, 6 weeks of stable antidepressants/augmenting agents 6. Sixth grade reading level 7. Ability to provide consent For the PTSD-only group, inclusion criteria are: 1. Female/Male veterans 2. 18 to 75 years old 3. Meets DSM-5 criteria for chronic PTSD or subthreshold PTSD \[meets criterion A (traumatic event), criterion B (intrusion symptoms), and 2 of the following 3 criteria: C (avoidance symptoms), D (negative alterations in cognitions and mood), or E (marked alterations in arousal and reactivity)\] 4. Does not meet DSM-5 criteria for MDD, single or recurrent, moderate-severe without psychotic features 5. If applicable, 6 weeks of stable antidepressants/augmenting agents 6. Sixth grade reading level 7. Ability to provide consent Exclusion Criteria: For the PTSD+MDD group, exclusion criteria are: 1. Inability or unwillingness to provide written informed consent 2. Moderate/severe cognitive impairment 3. Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition 4. History of moderate or severe traumatic brain injury 5. History of comorbid substance disorder within 1 month of screening 6. Prior use of ketamine as an antidepressant 7. Clinically unstable medical illness 8. For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study 9. Imminent risk of suicidal/homicidal ideation and/or behavior 10. Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.) For the Healthy Controls group, exclusion criteria are: 1. Inability or unwillingness to provide written informed consent 2. Moderate/severe cognitive impairment 3. History of any major medical or psychiatric disorders 4. Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition 5. History of moderate or severe traumatic brain injury 6. History of comorbid substance disorder within 1 month of screening 7. Prior use of ketamine as an antidepressant 8. Clinically unstable medical illness 9. For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study 10. Imminent risk of suicidal/homicidal ideation and/or behavior 11. Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.) For the Depression-only group, exclusion criteria are: 1. Inability or unwillingness to provide written informed consent 2. Moderate/severe cognitive impairment 3. Meet DSM-5 criteria for PTSD or subthreshold PTSD 4. Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition 5. History of moderate or severe traumatic brain injury 6. History of comorbid substance disorder within 1 month of screening 7. Prior use of ketamine as an antidepressant 8. Clinically unstable medical illness 9. For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study 10. Imminent risk of suicidal/homicidal ideation and/or behavior 11. Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.) For the PTSD-only group, exclusion criteria are: 1. Inability or unwillingness to provide written informed consent 2. Moderate/severe cognitive impairment 3. Meet DSM-5 criteria for a diagnosis of MDD, single or recurrent, moderate to severe 4. Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition 5. History of moderate or severe traumatic brain injury 6. History of comorbid substance disorder within 1 month of screening 7. Prior use of ketamine as an antidepressant 8. Clinically unstable medical illness 9. For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study 10. Imminent risk of suicidal/homicidal ideation and/or behavior 11. Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.)

Where

1 study site

FacilityCityRegionCountry
Minneapolis Veterans Affairs Health Care SystemMinneapolisMinnesotaUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT04032301 on ClinicalTrials.gov →

Last updated in the registry 2025-06-27. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits